Anti insulin-like growth factor I receptor immunoliposomes: A single formulation combining two anticancer treatments with enhanced therapeutic efficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 2, 2010, Pages 943-952

  Hantel, Constanze ^a   Lewrick, Felicitas ^b   Schneider, Sebastian ^b   Zwermann, Oliver ^a   Perren, Aurel ^c   Reincke, Martin ^a   Süss, Regine ^b   Beuschlein, Felix ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOLIPOSOME; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TISSUE MICROARRAY; TUMOR XENOGRAFT;

EID: 76149110071     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1980     Document Type: Article

References (45)

1. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395-401
2. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757-762
3. Maggard MA, O'Connell JB, Ko CY 2004 Updated population-based review of carcinoid tumors. Ann Surg 240:117-122
4. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072
5. Kaltsas GA, Besser GM, Grossman AB 2004 The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458-511
6. Arnold R, Rinke A, Schmidt Ch, Hofbauer L 2005 Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol 19:649-656
7. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K, Watkinson A 2005 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54(Suppl 4):iv1-iv16
8. Oberg K 2004 Management of neuroendocrine tumours. Ann Oncol 15(Suppl 4):iv293-iv298
9. Ouban A, Muraca P, Yeatman T, Coppola D 2003 Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34:803-808
10. Singleton JR, Randolph AE, Feldman EL 1996 Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 56:4522-4529
11. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW 2005 Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65:3781-3787
12. LogiéA, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y, Gicquel C 1999 Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol 23:23-32
13. Shimizu M, Deguchi A, Hara Y, Moriwaki H, Weinstein IB 2005 EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Commun 334:947-953
14. PavelićJ, PavelićL, Karadza J, Krizanac S, UnesićJ, Spaventi S, PavelićK 2002 Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma.MolMed8:149- 157
15. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A, Baserga R 1994 Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14:3604-3612
16. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira Jr A, Dalino P, Salahuddin N, Korbonits M, Grossman AB 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 87:168-181
17. Van Gompel JJ, ChenH2004 Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 136:1297-1302
18. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60:4573-4581
19. Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85: 54-60
20. Ryan PD, Goss PE 2008 The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13: 16-24
21. Bähr C, Groner B 2004 The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res 14:287-295
22. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R1993 Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102-1106
23. Martins AS, Mackintosh C, Martin DH, Campos M, Hernández T, Ordónez JL, de Alava E 2006 Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 12:3532-3540
24. Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverría C, Hofmann F, Krystal GW 2005 The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 11:1563-1571
25. Clemmons DR 2007 Modifying IGFI activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6:821-833
26. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL 2003 A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912-8921
27. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N 2005 A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316-328
28. Toretsky JA, Thakar M, Eskenazi AE, Frantz CN 1999 Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res 59:5745-5750
29. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD 2005 Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073
30. Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R, Ellis LM 2007 Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Ann Surg Oncol 14:2838-2846
31. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D 1999 Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743
32. Harrington KJ, Syrigos KN, Vile RG 2002 Liposomally targeted cytotoxic drugs for the treatment of cancer. J Pharm Pharmacol 54:1573-1600
33. Gabizon A, Shmeeda H, Barenholz Y 2003 Pharmacokinetics of pegylated liposomal doxorubicin: review of animal andhumanstudies. Clin Pharmacokinet 42:419-436
34. Tardi P, Bally MB, Harasym TO 1998 Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32:99-118
35. Maruyama K 2000 In vivo targeting by liposomes. Biol Pharm Bull 23:791-799
36. Li SL, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y 1993 Two new monoclonal antibodies against the α subunit of the human insulinlike growth factor-I receptor. Biochem Biophys Res Commun 196: 92-98
37. Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A 2008 Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 32:420-425
38. Parekh D, Ishizuka J, Townsend Jr CM, Haber B, Beauchamp RD, Karp G, Kim SW, Rajaraman S, Greeley Jr G, Thompson JC 1994 Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 9:83-90
39. Gantert M, Lewrick F, Adrian JE, Rössler J, Steenpass T, Schubert R, Peschka-Süss R 2009 Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors. Pharm Res 26:529-538
40. Charrois GJ, Allen TM 2003 Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 306:1058-1067
41. Theodoulou M, Hudis C 2004 Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 100:2052-2063
42. Gabizon AA, Shmeeda H, Zalipsky S 2006 Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 16: 175-183
43. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271-284
44. Torchilin VP 2000 Drug targeting. Eur J Pharm Sci 11(Suppl 2): S81-S91
45. Shang Y,MaoY, Batson J, Scales SJ, Phillips G, Lackner MR, Totpal K, Williams S, Yang J, Tang Z, Modrusan Z, Tan C, Liang WC, Tsai SP, Vanderbilt A, Kozuka K, Hoeflich K, Tien J, Ross S, Li C, Lee SH, Song A, Wu Y, Stephan JP, Ashkenazi A, Zha J 2008 Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther 7:2599-2608